Emprumapimod

DB17603InvestigationalSmall molecule

Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 14
Curator reviewed
Formula / weight: C₂₄H₂₉F₂N₅O₃ · 473.525 g/mol (avg)
Code names: PF-06802861 · PF-07265803

Resolves to

Compound

UNII4JG61K4659CAS765914-60-1

Structure

InChIKeyJOOOJNJPZINWHM-IBGZPJMESA-NSMILESCC(C)CN1N=CC2=CC(OC3=CC=C(F)C=C3F)=C(C=C12)C(=O)N[C@@H](CCN(C)C)C(N)=O

Targets

Q16539MAPK14

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Emprumapimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account